Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma

Medicine & Life Sciences

• AZD 6244 100%
• Genetic Therapy 56%
• Melanoma 50%
• Mutation 33%
• Mitogen-Activated Protein Kinase Kinases 15%
• Glutamine 9%
• Lysine 9%
• Arginine 8%
• temsirolimus 6%
• Dacarbazine 5%
• Erlotinib Hydrochloride 5%
• ras Genes 5%
• Valine 5%
• Nonsense Codon 5%
• Docetaxel 5%
• Glycine 4%
• Neuroblastoma 4%
• Oncogenes 4%
• Sarcoma 4%
• Proportional Hazards Models 4%
• Glutamic Acid 4%
• Genes 3%
• Pharmaceutical Preparations 1%
• Neoplasms 1%
• Therapeutics 0%